🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06962436
Recruiting Not applicable

RAB Versus Ultrathin Bronchoscopy With VBN in the Diagnosis of PPNs

NCT06962436 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai Chest Hospital
Phase
Not applicable
Started
2025-07-02
Last updated
2026-03-25

Condition(s) studied

Peripheral Pulmonary Nodules

Investigational drug(s) / intervention(s)

Robotic bronchoscopy systemUltrathin bronchoscope combined with virtual bronchoscopic navigation

Robotic bronchoscopy system: Utilization of a robotic bronchoscopy system for the biopsy of patients with peripheral pulmonary lesions suspected of malignancy

Ultrathin bronchoscope combined with virtual bronchoscopic navigation: Utilization of ultrathin bronchoscope combined with virtual bronchoscopic navigation for the biopsy of patients with peripheral pulmonary lesions suspected of malignancy

Study summary

The purpose of this study is to evaluate whether the diagnostic yield of robotic-assisted bronchoscopy is not inferior to that of the virtual bronchoscopic navigation combined with ultrathin bronchoscopy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Age ≥ 18 years, regardless of gender; 2. Patients with peripheral lung nodules of suspected malignancy on chest CT who require non-surgical biopsy; 3. Patients who voluntarily consent to undergo bronchoscopy and meet the requirements for the bronchoscopy; 4. Patients should understand the purpose of the trial, demonstrate good compliance with the examinations and follow-ups, and voluntarily participate in the clinical trial and sign the informed consent form. Exclusion Criteria: 1. Presence of contraindications for bronchoscopy, including: active massive hemoptysis; recent myocardial infarction or unstable angina; severe cardiac or pulmonary dysfunction; severe hypertension and arrhythmias; uncorrectable bleeding tendencies or severe coagulation disorders (such as platelet count \<60×10\^9/L), uremia; severe pulmonary artery hypertension; severe superior vena cava syndrome; intracranial hypertension; acute cerebrovascular events; aortic dissection or aneurysm; multiple bullae; extreme systemic exhaustion; 2. Patients with pure ground-glass nodules suspected of malignancy on chest CT; 3. Female patients who are breastfeeding, pregnant, or planning pregnancy; 4. Patients with electromagnetic active implantable medical devices; 5. Subjects allergic to anesthetics; or with a history of multiple severe allergies, hereditary allergy history; 6. Those who have participated in or are currently participating in drug clinical trials within 3 months before screening, or have participated in other medical device clinical trials within 30 days; 7. Any other conditions deemed unsuitable for participation in this clinical trial by the investigator.

Primary outcome measure(s)

Trial sites (5)

FacilityCityRegionStatus
Shandong Public Health Clinical Center Jinan Shandong Recruiting
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai Shanghai Municipality Recruiting
Shanghai Chest Hospital Shanghai Shanghai Municipality Recruiting
Zhongshan Hospital,Fudan University Shanghai Shanghai Municipality Recruiting
Sir Run Run Shaw Hospital , affiliated with the Zhejiang University School of Medicine Hangzhou Zhejiang Recruiting

More Shanghai Chest Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06962436 on ClinicalTrials.gov ↗ ← All trials in China